Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


 

E-learning: Quarterly Focus on Genitourinary Cancer | RCC

12/09/2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this second episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Renal Cell Carcinoma from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: Prof. John Haanen, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam Hans Westgeest, MD, medical oncologist, Amphia Ziekenhuis, Breda Astrid van der Veldt, MD, PhD, medical oncologist, Erasmus MC, Rotterdam Program: Invited speaker: Kathleen Mahoney, MD, PhD, medical oncologist, Beth Israel Deaconess Medical Center, Boston Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma N Engl J Med 378, 2018 Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Nature Medicine 24, 2018

 

ASCO 2018 Results of the TAILORx trial

27/06/2018

Joseph Sparano, oncologist at Montefiore Medical Center, explains the results of the TAILORx trial, which he presented during the plenary session at ASCO 2018. This trial attempted to incorporate a gene expression test into clinic decision making for hormone receptor positive breast cancer.

  • 00:06:50
 

E-learning: Quarterly Focus on Genitourinary Cancer | Prostate Cancer

23/05/2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Two pivotal, international publications from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: André Bergman MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam Martijn Lolkema MD, PhD, medical oncologist, Erasmus MC, Rotterdam Niven Mehra MD, PhD, medical oncologist, Radboudumc, Nijmegen Program: Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial J Clin Oncol 36, 2018 Speaker: Prof. Gert De Meerleer MD, PhD, radiation oncologist, UZ Leuven, Belgium Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide J Clin Oncol 35, 2017 Speaker: Jun Luo MD, PhD, cell and molecular biologist, Brady Urological Institute, US

 

ASCO GU 2018: Renal Cell Carcinoma News Program

22/03/2018

This year the ASCO Genitourinary Cancers Symposium took place in San Francisco from February 8th - 10th. In this Renal Cell Carcinoma News Program, we focus on the highlights for RCC at this congress. Moderator Catherine Hood and a panel of international experts discuss the following topics: Adjuvant systemic therapy Cabozantinib in the first line treatment of metastatic RCC The NIVOREN trial that investigates nivolumab in a ‘real world setting’ Combination treatments with VEGF and PD1/PD-L1 inhibition Advances in treatment for papillary RCC Speakers: Prof. Joaquim Bellmunt, MD, medical oncologist, Dana-Farber/Brigham and Women's Cancer Center, Boston Daniel George, MD, medical oncologist, Duke Cancer Center, Durham Jeanny Aragon-Ching, MD, medical oncologist, Inova Fairfax hospital, Fairfax Sumanta Pal, MD, medical oncologist, City of Hope Comprehensive Cancer Center, Duarte Moderator: Catherine Hood

  • 00:39:40
 

E-learning: Quarterly Focus on Breast Cancer

22/03/2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not have always sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks.eu/OncologyTV has developed a new program format, the 'Quarterly Focus', which brings together an expert panel and the authors of relevant, selected publications in an innovative way to explain and discuss the new data. Two pivotal, international publications from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the unique possibility to gain more insight into the selected publications and to interact with the expert panel and the authors. The expert panel consists of: Gabe Sonke, MD, Ph.D, medical oncologist, NKI-AVL Amsterdam, Netherlands Ester Siemerink, MD, Ph.D, medical oncologist, Ziekenhuis Groep Twente, Hengelo/Almelo, Netherlands Rianne Oosterkamp, MD, medical oncologist, Haaglanden Medisch Centrum, Den Haag, Netherlands Invited speakers: Prof. George Sledge, MD, medical oncologist Stanford University School of Medicine, California, US MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy J Clin Oncol, 2017 Prof. Laura van 't Veer, molecular biologist UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades JAMA Oncol, 2017

 

ASCO GU 2018: Oligoprogressive mRCC

22/03/2018

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined what the impact was of switching systemic treatment after radiosurgery for oligoprogressive, metastatic renal cell carcinoma.

  • 00:05:25

Click here to select your areas of interest

Areas of interest

Select to filter on program types

Quarterly focus 19/12/2018

Quarterly Focus on Genitourinary Cancer: highlights in prostate carcinoma (part 2)

In each Quarterly Focus MEDtalks Oncology brings you the unique opportunity to gain more insight into two pivotal publications on Genitourinary Cancer. In the fourth episode (watch episode 1 on prostate cancer (part 1), episode 2 on renal cell carcinoma and episode 3 on bladder cancer on-demand) two international publications on prostate cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. During the live broadcast on Wednesday 19th of December 8.30-9.30 PM CEST you have the possibility to interact with our expert panel and the authors and ask them your questions. The expert panel consist of: Niven Mehra, MD, PhD – medical oncologist, Radboudumc, Nijmegen Andre Bergman, MD, PhD – medical oncologist, Netherlands Cancer Institute, Amsterdam Theo de Reijke, MD, PhD - urologist, AMC, Amsterdam program: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer (LATITUDE) N Engl J M, July 27, 2017 Speaker: Karim Fizazi, MD, PhD - medical oncologist, Gustave Roussy Institute, Villejuif, France Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial The Lancet, Oct 21, 2018 Speaker: Prof. Nicholas James, PhD - medical oncologist, University of Birmingham, UK Sign up for this live program

Congresnieuws 13/12/2018

EMUC 2018: Best Abstract Award

Dr. Christian Fankhauser, urologist at the UniversitätsSpital Zürich in Switzerland, has won the Best Abstract Award at the EMUC 2018. He is currently testing an algorithm designed to standardize tissue examination in order to get more uniformity in the Gleason Score assessment.

Congresnieuws 13/12/2018

EMUC 2018: Highlights

Prof. Alberto Briganti, professor in the urology at the IRCCS Ospedale San Raffaele in Italy, is a member of the EMUC scientific committee on behalf of the EAU. He shares with us his personal highlights of the EMUC 2018, among which are the STAMPEDE and HORRAD trials and new radiological developments.

Congresnieuws 13/12/2018

EMUC 2018: HORRAD trial

In the HORRAD trial patients with prostate cancer were randomized to receive either local therapy and ADT or ADT alone. Dr. Liselotte Boevé, urologist at VU Medisch Centrum in Amsterdam, presents us the results.

Congresnieuws 13/12/2018

EMUC 2018: Frail patients and the CARMENA trial

Dr. Umberto Capitanio, urologist at the IRCCS Ospedale San Raffaele in Italy and chief editor of the kidney cancer section of the UROONCO educational platform, talks about the EMUC 2018 discussion about frail patients. Furthermore he mentions the discussion about the Carmena trial in which nephrectomy plus adjuvant sunitinib is compared to sunitinib alone in patients with metastatic renal cell cancer.

Congresnieuws 13/12/2018

EMUC 2018: STAMPEDE trial

Prof. Nicholas James, oncologist at the University Hospitals Birmingham NHS Trust (UK), talks us through the new results of the STAMPEDE trial. Do the results of abiraterone differ in patients with high risk metastatic prostate cancer as compared to patients in the low risk category? And is there any benefit of adding radiotherapy to systemic therapy?

Congresnieuws 13/12/2018

EMUC 2018: POTOMAC & ALBAN trials

Dr. Evanguelos Xylinas, urologist at Cochin Hospital, Paris Descartes University (France), is chief editor of the bladder cancer section of the UROONCO educational platform and talks about the POTOMAC trial (durvalumab plus BCG vs. BCG) and the ALBAN trial (atezolizumab plus BCG vs. BCG).

Congresnieuws 13/12/2018

EMUC 2018: Delaying metastasizing with enzalutamide or apalutamide

Can metastasizing of castration resistant prostate cancer be postponed by using enzalutamide or apalutamide? Dr. Karim Fizazi, medical oncologist at the Institut Gustave Roussy in France, concludes this is the case. Furthermore, he talks about the first results of darolutamide.

Congresnieuws 13/12/2018

EMUC 2018: POUT trial

Dr. Alison Birtle (UK) is thrilled about the results of the POUT trial. This trial examined the benefit of adjuvant chemotherapy after nephroureterectomy in patients with upper tract urothelial carcinoma.

Congresnieuws 12/12/2018

EMUC 2018: Take home messages

Dr. Laurence Albiges, medical oncologist at the Institut Gustave Roussy (France), shares with us her take home messages of EMUC 2018, several of which might have practice changing potential. 

Congresnieuws 12/12/2018

EMUC 2018: A European standard for prostate cancer

Dr. Peter Albers, urologist in the Üniversitätsklinikum Düsseldorf in Germany, speaks about the joint effort to come to a European standard for the treatment of prostate cancer during the EMUC 2018 consensus meeting.